Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Linezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 1.00 |
| ▸ | MAOA | P21397 | 7/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | SDHA | P31040 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CALML3 | P27482 | 1/20 | 1.00 |
| ▸ | F10 | P00742 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linezolid SCHEMBL30226927 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30638355 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL7992562 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL1561095 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5027 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL374752 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2222512 | 1.00 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2280731 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2279924 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2277149 | 0.99 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023065521-A1 | GAS CHROMATOGRAPHY-MASS SPECTROMETRY COMBINED METHOD FOR DETERMINING GENOTOXIC IMPURITY 1,3-DICHLORO-2-PROPANOL | 浙江海正药业股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| US-20100261763-A1 | ANTIBACTERIAL AGENTS AND METHODS OF USE THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2010-10-14 | — | — | US | disclosed |
| US-7737164-B2 | Cyanopyridine antibacterial agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20080009528-A1 | ANTIBACTERIAL AGENTS AND RELATED SCREENING METHODS USING SMALL MOLECULE MACROARRAYS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-01-10 | — | — | US | disclosed |
| EP-1745028-A2 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006110155-A1 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-10-19 | — | — | WO | disclosed |
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009528-A1 | ANTIBACTERIAL AGENTS AND RELATED SCREENING METHODS USING SMALL MOLECULE MACROARRAYS | PCNA, ABCG2, API5 | MAOB 929/4885MAOA 1035/4885PTGS1 2957/4885 |
| US-20100261763-A1 | ANTIBACTERIAL AGENTS AND METHODS OF USE THEREOF | FDPS, CYP3A5, ABCG2 | MAOB 387/4885MAOA 813/4885PTGS1 2194/4885 |
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | F9, Q6ZSR9, TBCD | MAOB 2551/4885MAOA 1756/4885PTGS1 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.